Evaluation of CCR2 in Patients Post Myocardial Infarction

Description

To determine the feasibility of 64Cu-DOTA-ECL1i, an investigational PET imaging drug, at the cellular level in the myocardium for individuals who have suffered a heart attack or who have other inflammatory heart disease.

Conditions

Heart Diseases

Study Overview

Study Details

Study overview

To determine the feasibility of 64Cu-DOTA-ECL1i, an investigational PET imaging drug, at the cellular level in the myocardium for individuals who have suffered a heart attack or who have other inflammatory heart disease.

Preliminary Evaluation of 64Cu-DOTA-ECL1i in Patients Post-ST-Elevation Myocardial Infarction(STEMI)

Evaluation of CCR2 in Patients Post Myocardial Infarction

Condition
Heart Diseases
Intervention / Treatment

-

Contacts and Locations

Saint Louis

Washington University School of Medicine, Saint Louis, Missouri, United States, 63110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Healthy Volunteers:
  • 2. Age 21 to 80 years of either sex, any race
  • 3. Capable of lying still and supine within the PET/CT and PET/MR scanner for 1 hour and follow instructions for breathing protocol during the CT portion
  • 4. No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year
  • 5. No known history of cardiac. pulmonary, hepatic, or renal disease or diabetes
  • 6. No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions
  • 7. Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol.
  • 1. Age 21 to 80 years of either sex, any race who have suffered a STEMI within the past 6 months as well as other forms of inflammatory heart disease including sarcoidosis, myocarditis, cardiomyopathy, injected cardiovascular implantable electronic devices pacemakers/LVAD
  • 2. Are clinically stable to undergo imaging with either PET/MR or PET/CT.
  • 3. Capacity to give written informed consent and ability to follow study procedures
  • 4. Pre-menopausal women must have a negative urine pregnancy test within 24 hours prior to the administration of 64-Cu-DOTA-ECL1i.
  • 1. Currently enrolled in another study using an investigational drug
  • 2. Angina
  • 3. Uncontrolled heart failure
  • 4. uncontrolled hypertension baseline hypotension below 90/50
  • 5. Has any condition that in the opinion of the PI or designee that could increase risk to the subject
  • 6. Is deemed likely to be unable to perform all research procedures
  • 7. Have contraindications to PET/CT imaging like claustrophobia
  • 8. Have contraindication to gadolinium
  • 9. Pregnant or breastfeeding
  • 10. Currently using recreational drubs
  • 11. Body weight of more than 300 lbs
  • 12. Active symptoms or history of cardiac, pulmonary, hepatic or renal disease or diabetes
  • 13. currently taking any prescription medications
  • 14. Presence of an implanted device incompatible with CT or MRI scanning Inflammatory Heart Disease

Ages Eligible for Study

21 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Washington University School of Medicine,

Study Record Dates

2025-11-24